Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific commences treatment in Blazer catheter trial

Boston Scientific commences treatment in Blazer catheter trial

17th January 2013

Boston Scientific's new clinical study of its Blazer open-irrigated temperature ablation catheter has commenced, with the first patient having received treatment as part of the trial.

The Zero AF study aims to evaluate the safety and efficacy of the Blazer device in treating patients with symptomatic drug-refractory paroxysmal atrial fibrillation, with just over 470 subjects set to take part.

Boston Scientific is seeking US regulatory approval for the catheter, which features an advanced tip design for irrigated ablation and retains the proven reliability performance of the Blazer platform.

The company has already received European CE Mark accreditation for the device and considers the product an important part of its offering in the growing electrophysiology market.

Joe Fitzgerald, president of the cardiac rhythm management business at Boston Scientific, said: "Launching this trial highlights our continued commitment to clinicians and patients through the expansion of our electrophysiology ablation business including the high-growth segment of complex ablations."

This comes after the firm began a clinical trial assessing the benefits of its next-generation Ingevity pacing leads last month.ADNFCR-8000103-ID-801524011-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.